631 related articles for article (PubMed ID: 32595636)
1. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
2. Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists.
Macedo AB; Novis CL; Bosque A
Front Immunol; 2019; 10():2450. PubMed ID: 31681325
[TBL] [Abstract][Full Text] [Related]
3. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
[TBL] [Abstract][Full Text] [Related]
4. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
5. Clinical Interventions in HIV Cure Research.
Rasmussen TA; Søgaard OS
Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.
Moody MA; Santra S; Vandergrift NA; Sutherland LL; Gurley TC; Drinker MS; Allen AA; Xia SM; Meyerhoff RR; Parks R; Lloyd KE; Easterhoff D; Alam SM; Liao HX; Ward BM; Ferrari G; Montefiori DC; Tomaras GD; Seder RA; Letvin NL; Haynes BF
J Virol; 2014 Mar; 88(6):3329-39. PubMed ID: 24390332
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells.
Alvarez-Carbonell D; Garcia-Mesa Y; Milne S; Das B; Dobrowolski C; Rojas R; Karn J
Retrovirology; 2017 Feb; 14(1):9. PubMed ID: 28166799
[TBL] [Abstract][Full Text] [Related]
9. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
Bricker KM; Chahroudi A; Mavigner M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452425
[TBL] [Abstract][Full Text] [Related]
10. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
Rochat MA; Schlaepfer E; Speck RF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
[TBL] [Abstract][Full Text] [Related]
11. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
12. TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure.
Hvilsom CT; Søgaard OS
Front Immunol; 2021; 12():704617. PubMed ID: 34630386
[TBL] [Abstract][Full Text] [Related]
13. Between a shock and a hard place: challenges and developments in HIV latency reversal.
Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
15. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
Front Immunol; 2020; 11():599083. PubMed ID: 33281825
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
17. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
18. Could DNA-reactive B lymphocytes be activated through HIV-1 DNA-stimulation involving BCR/TLR-9 pathway to yield antibodies targeting viral DNA?
Norelli S
Med Hypotheses; 2014 Dec; 83(6):659-63. PubMed ID: 25441838
[TBL] [Abstract][Full Text] [Related]
19. Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.
Ferrari G; Pollara J; Tomaras GD; Haynes BF
J Infect Dis; 2017 Mar; 215(suppl_3):S152-S159. PubMed ID: 28520963
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor agonists as adjuvants for HIV vaccines.
Stevceva L
Curr Med Chem; 2011; 18(33):5079-82. PubMed ID: 22050755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
